Trial · NCT03192176
Results by group3,392
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 3,392
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Placebo BID | -4.2 | Standard Error 0.65 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 15 mg BID | -6.1 | Standard Error 0.65 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 30 mg BID | -7.2 | Standard Error 0.64 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 60 mg BID | -7.0 | Standard Error 0.62 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 90 mg BID | -7.7 | Standard Error 0.65 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 30 mg QD | -6.5 | Standard Error 0.65 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 60 mg QD | -7.2 | Standard Error 0.61 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | Fezolinetant 120 mg QD | -6.6 | Standard Error 0.63 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Placebo | -5.3 | Standard Error 0.58 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 15 mg BID | -7.2 | Standard Error 0.54 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 30 mg BID | -7.5 | Standard Error 0.56 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 60 mg BID | -7.6 | Standard Error 0.55 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 90 mg BID | -8.0 | Standard Error 0.58 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 30 mg QD | -7.4 | Standard Error 0.58 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 60 mg QD | -7.9 | Standard Error 0.54 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | Fezolinetant 120 mg QD | -7.4 | Standard Error 0.57 | VMS per day | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | Placebo | -0.3 | Standard Error 0.15 | Score on a scale | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | Fezolinetant 15 mg BID | -0.8 | Standard Error 0.14 | Score on a scale | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | Fezolinetant 30 mg BID | -0.9 | Standard Error 0.15 | Score on a scale | |
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | Fezolinetant 60 mg BID | -1.2 | Standard Error 0.14 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03192176/results